Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2022

30-05-2022 | Fertility | Meta- Analysis

Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis

Authors: Wenjia Yang, Chu Lin, Mengqian Zhang, Fang Lv, Xingyun Zhu, Xueyao Han, Xiaoling Cai, Linong Ji

Published in: Endocrine | Issue 2/2022

Login to get access

Abstract

Purpose

Current knowledge about the ovarian reserve in patients with type 1 diabetes is inconsistent and based on studies with small sample size. This meta-analysis aimed to produce a comprehensive evaluation on the ovarian reserve of type 1 diabetes female patients and to analyze the associated factors with the ovarian reserve.

Methods

Systematic searches were conducted for studies published from the inception to December 2021. Original human observational studies either with case-control, cross-sectional, or longitudinal design evaluating ovarian reserve markers between type 1 diabetes patients and healthy controls were included. Levels of anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH), and estradiol (E2) were extracted.

Results

It was indicated that women with type 1 diabetes were associated with decreased levels of AMH compared with healthy controls (weighted mean difference [WMD] −0.70 ng/ml, 95% confidence intervals [CI] −1.05 to −0.34 ng/ml, P = 0.0001). Subgroup analyses stratified by age showed that adult patients with type 1 diabetes were associated with decreased levels of AMH (WMD −0.70 ng/ml, 95% CI −1.06 to −0.34 ng/ml, P = 0.0001) and FSH (WMD −1.07 IU/L, 95% CI −1.75 to −0.39 IU/L, P = 0.002) compared with healthy controls. Meta-regression analysis showed no significant correlation between AMH, FSH, and clinical factors, while level of E2 was negatively correlated with daily insulin doses and glycosylated hemoglobin A1c (HbA1c) values.

Conclusion

According to this meta-analysis, type 1 diabetes might be associated with decreased AMH levels. Further studies using different markers and fertility outcomes focus on the ovarian reserve of women with type 1 diabetes are urgently needed.
Appendix
Available only for authorised users
Literature
1.
S.U. Park, L. Walsh, K.M. Berkowitz, Mechanisms of ovarian aging. Reproduction 162, R19–33 (2021)PubMedCrossRef
2.
H. Xu, M. Zhang, H. Zhang, H. Zhang, K. Alpadi, K.L. Wang, R. Li, J. Qiao, Clinical applications of serum anti-müllerian hormone measurements in both males and females: an update. Innovation 9, 100091 (2021)
3.
L.M.E. Moolhuijsen, J.A. Visser, Anti-müllerian hormone and ovarian reserve: update on assessing ovarian function. J. Clin. Endocrinol. Metab. 105, 3361–3373 (2020)PubMedCentralCrossRef
4.
D.B. Seifer, G. Lambert-Messerlian, J.W. Hogan, A.C. Gardiner, A.S. Blazar, C.A. Berk, Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil. Steril. 67, 110–114 (1997)PubMedCrossRef
5.
F.J. Broekmans, J. Kwee, D.J. Hendriks, B.W. Mol, C.B. Lambalk, A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update 12, 685–718 (2016)CrossRef
6.
S.L. Broer, J. van Disseldorp, K.A. Broeze, M. Dolleman, B.C. Opmeer, P. Bossuyt, M.J. Eijkemans, B.W. Mol, F.J. Broekmans; IMPORT study group, Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum. Reprod. Update 19, 26–36 (2013)PubMedCrossRef
7.
A. Lass, J. Skull, E. McVeigh, R. Margara, R.M. Winston, Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in vitro fertilization can predict poor response. Hum. Reprod. 12, 294–297 (1997)PubMedCrossRef
8.
9.
K. Kjaer, C. Hagen, S.H. Sandø, O. Eshøj, Epidemiology of menarche and menstrual disturbances in an unselected group of women with insulin-dependent diabetes mellitus compared to controls. J. Clin. Endocrinol. Metab. 75, 524–529 (1992)PubMed
10.
K.K. Danielson, M. Palta, C. Allen, D.J. D’Alessio, The association of increased total glycosylated hemoglobin levels with delayed age at menarche in young women with type 1 diabetes. J. Clin. Endocrinol. Metab. 90, 6466–6471 (2005)PubMedCrossRef
11.
J.S. Dorman, A.R. Steenkiste, T.P. Foley, E.S. Strotmeyer, J.P. Burke, L.H. Kuller, C.K. Kwoh, Menopause in type 1 diabetic women: is it premature? Diabetes 50, 1857–1862 (2001)PubMedCrossRef
12.
N. Soto, G. Iñiguez, P. López, G. Larenas, V. Mujica, R.A. Rey, E. Codner, Anti-müllerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum. Reprod. 24, 2838–2844 (2009)PubMedCrossRef
13.
C. Kim, C. Karvonen-Gutierrez, S. Kong, V. Arends, M. Steffes, D.S. McConnell, J.F. Randolph Jr, S.D. Harlow, Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study. Fertil. Steril. 106, 1446–1452 (2016)PubMedPubMedCentralCrossRef
14.
F. Yarde, W. Spiering, A. Franx, F.L.J. Visseren, M.J.C. Eijkemans, H.W. de Valk, F.J.M. Broekmans; OVADIA Study Group, Association between vascular health and ovarian ageing in type 1 diabetes mellitus. Hum. Reprod. 31, 1354–1362 (2016)PubMedCrossRef
15.
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009)PubMedPubMedCentralCrossRef
16.
Rostom, A., Dubé, C., Cranney, A., Saloojee, N., Sy, R., Garritty, C., Sampson, M., Zhang, L., Yazdi, F., Mamaladze, V., Pan, I. McNeil, J., Moher, D., Mack, D., Patel, D. Celiac disease. Evid. Rep. Technol. Assess. 104, 1–6 (2004).
17.
S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample. Bmc. Med. Res. Methodol. 5, 13 (2005)PubMedPubMedCentralCrossRef
18.
V. Calcaterra, R.E. Nappi, G. Pelizzo, A. De Silvestri, R. Albertini, M. De Amici, E. Tenuta, F. Vinci, C. Mameli, G. Zuccotti, Insulin resistance and potential modulators of ovarian reserve in young reproductive-aged women with obesity and type 1 diabetes. Gynecol. Endocrinol. 37, 823–830 (2021)PubMedCrossRef
19.
E. Codner, D. Mook-Kanamori, R.A. Bazaes, N. Unanue, H. Sovino, F. Ugarte, A. Avila, G. Iñiguez, F. Cassorla, Ovarian function during puberty in girls with type 1 diabetes mellitus: response to leuprolide. J. Clin. Endocrinol. Metab. 90, 3939–3945 (2005)PubMedCrossRef
20.
E. Codner, N. Soto, P. Lopez, L. Trejo, A. Avila, F.C. Eyzaguirre, G. Iniguez, F. Cassorla, Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 91, 2250–2256 (2006)PubMedCrossRef
21.
A. Łebkowska, A. Adamska, M. Karczewska-Kupczewska, A. Nikołajuk, E. Otziomek, R. Milewski, M. Górska, S. Wołczyński, I. Kowalska, Serum anti-Müllerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus. Metabolism 65, 804–811 (2016)PubMedCrossRef
22.
P. Kadiroğulları, E. Demir, P.Y. Bahat, H. Kıyak, K.D. Seckin, Evaluation of relationship between HbA1c levels and ovarian reserve in patients with type 1 diabetes mellitus. Gynecol. Endocrinol. 36, 426–430 (2020)PubMedCrossRef
23.
L.S. Hassan, R.S. Monson, K.K. Danielson, Oestradiol levels may differ between premenopausal women, ages 18-50, with type 1 diabetes and matched controls. Diabetes Metab. Res. Rev. 33, 2829 (2017)CrossRef
24.
R. Tal, D.B. Seifer, Ovarian reserve testing: a user’s guide. Am. J. Obstet. Gynecol. 217, 129–140 (2017)PubMedCrossRef
25.
J.G. Regensteiner, S. Golden, A.G. Huebschmann, E. Barrett-Connor, A.Y. Chang, D. Chyu, C.S. Fox, C. Kim, N. Mehta, J.F. Reckelhoff, J.E.B. Reusch, K.M. Rexrode, A.E. Sumner, F.K. Welty, N.K. Wegner, B. Anton, Sex Differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association. Circulation 132, 2424–2447 (2015)PubMedCrossRef
26.
Practice Committee of the American Society for Reproductive Medicine, Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil. Steril. 103, e9–17 (2015)
27.
Z. Jamil, S.S. Fatima, K. Ahmed, R. Malik, Anti-Müllerian hormone: above and beyond conventional ovarian reserve markers. Dis. Markers 2016, 5246217 (2016)PubMedPubMedCentralCrossRef
28.
M. Depmann, M.J. Faddy, Y.T. van der Schouw, P.H.M. Peeters, S.L. Broer, T.W. Kelsey, S.M. Nelson, F.J.M. Broekmans, The relationship between variation in size of the primordial follicle pool and age at natural menopause. J. Clin. Endocrinol. Metab. 100, e845–851 (2015)PubMedCrossRef
29.
M.R. Gohari, F.R. Tehrani, S. Chenouri, M. Solaymani-Dodaran, F. Azizi, Individualized predictions of time to menopause using multiple measurements of antimüllerian hormone. Menopause 23, 839–845 (2016)PubMedCrossRef
30.
A. La Marca, G. Sighinolfi, D. Radi, C. Argento, E. Baraldi, A.C. Artenisio, G. Stabile, A. Volpe, Anti-müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum. Reprod. Update 16, 113–130 (2010)PubMedCrossRef
31.
F.R. Tehrani, H. Erfani, L. Cheraghi, M. Tohidi, F. Azizi, Lipid profiles and ovarian reserve status: a longitudinal study. Hum. Reprod. 29, 2522–2529 (2014)PubMedCrossRef
32.
N.M. Daan, B.C. Fauser, Menopause prediction and potential implications. Maturitas 82, 257–265 (2015)PubMedCrossRef
33.
M.L. Griffin, S.A. South, V.I. Yankov, R.A. Booth Jr, C.M. Asplin, J.D. Veldhuis, W.S. Evans, Insulin-dependent diabetes mellitus and menstrual dysfunction. Ann. Med. 26, 331–340 (1994)PubMedCrossRef
34.
K. Kjaer, C. Hagen, S. Sando, O. Eshoj, Epidemiology of menarche and menstrual disturbances in an unselected group of women with insulindependent diabetes mellitus compared to control subjects. J. Clin. Endocrinol. Metab. 75, 524–529 (1992)PubMed
35.
A. Yeshaya, R. Orvieto, D. Dicker, M. Karp, Z. Ben-Rafael, Menstrual characteristics of women suffering from insulin-dependent diabetes mellitus. Int J. Fertil. 40, 269–273 (1995)
36.
A.S. Chang, A.N. Dale, K.H. Moley, Maternal diabetes adversely affects preovulatory oocyte maturation, development, and granulosa cell apoptosis. Endocrinology 146, 2445–2453 (2005)PubMedCrossRef
37.
S.A. Colton, P.G. Humpherso, H.J. Lees, S.M. Downs, Physiological changes in oocyte-cumulus cell complexes from diabetic mice that potentially influence meiotic regulation. Biol. Reprod. 69, 761–770 (2003)PubMedCrossRef
38.
C. Tatone, F. Amicarelli, M.C. Carbone, P. Monteleone, D. Caserta, R. Marci, P.G. Artini, P. Piomboni, R. Focarelli, Cellular and molecular aspects of ovarian follicle ageing. Hum. Reprod. Update 14, 131–142 (2008)PubMedCrossRef
39.
E. Diamanti-Kandarakis, C. Piperi, E. Patsouris, P. Korkolopoulou, D. Panidis, L. Pawelczyk, A.G. Papavassiliou, A.J. Duleba, Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem. Cell. Biol. 127, 581–589 (2007)PubMedCrossRef
40.
M.F. Wellons, J.J. Matthews, C. Kim, Ovarian aging in women with diabetes: an overview. Maturitas 96, 109–113 (2017)PubMedCrossRef
41.
R. Salvi, E. Castillo, M.J. Voirol, M. Glauser, J.P. Rey, R.C. Gailard, P. Vollenweider, F.P. Pralong, Gonadotropin-releasing hormone-expressing neurons immortalized conditionally are activated by insulin: implication of the mitogen-activated protein kinase pathway. Endocrinology 147, 816–826 (2006)PubMedCrossRef
42.
J.C. Brüning, D. Gautam, D.J. Burks, J. Gillette, M. Schubert, P.C. Orban, R. Klein, W. Krone, D. Müller-Wieland, C.R. Kahn, Role of brain insulin receptor in control of body weight and reproduction. Science 289, 2122–2125 (2000)PubMedCrossRef
43.
J.M. Castellano, V.M. Navarro, J. Roa, R. Pineda, M.A. Sánchez-Garrido, D. García-Galiano, E. Vigo, C. Dieguez, E. Aguilar, L. Pinilla, M. Tena-Sempere, Alterations in hypothalamic KiSS-1 system in experimental diabetes: early changes and functional consequences. Endocrinology 150, 784–794 (2009)PubMedCrossRef
44.
B. Lawrenz, J. Henes, M. Henes, E. Neunhoeffer, M. Schmalzing, T. Fehm, I. Kïtter, Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 20, 1193–1197 (2011)PubMedCrossRef
45.
W. Luo, P. Mao, L. Zhang, X. Chen, Z. Yang, Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis. Ann. Palliat. Med. 9, 207–215 (2020)PubMedCrossRef
46.
M.E. Clowse, S.C. Copland, T.C. Hsieh, S.C. Chow, G.S. Hoffman, P.A. Merkel, R.F. Spiera, J.C. Davis Jr, W.J. McCune, S.R. Ytterberg, E.W. St Clair, N.B. Allen, U. Specks, J.H. Stone; WGET Research Group, Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener’s). Arthritis Care. Res. 63, 1777–1781 (2011)CrossRef
47.
C. Betterle, A. Rossi, S.D. Dalla Pria, A. Artifoni, B. Pedini, S. Gavasso, A. Caretto, Premature ovarian failure: autoimmunity and natural history. Clin. Endocrinol. 39, 35–43 (1993)CrossRef
48.
H.F. Escobar-Morreale, B. Roldán, R. Barrio, M. Alonso, J. Sancho, H. de la Calle, R. García-Robles, High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 85, 4182–4187 (2000)PubMed
49.
H.F. Escobar-Morreale, M. Belén Roldán-Martín, Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis. Diabetes Care 39, 639–648 (2016).PubMedCrossRef
50.
N. Moslehi, S. Shab-Bidar, F.R. Tehrani, P. Mirmiran, F. Azizi, Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. Menopause 25, 1046–1055 (2018)PubMedCrossRef
Metadata
Title
Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis
Authors
Wenjia Yang
Chu Lin
Mengqian Zhang
Fang Lv
Xingyun Zhu
Xueyao Han
Xiaoling Cai
Linong Ji
Publication date
30-05-2022
Publisher
Springer US
Published in
Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03091-y

Other articles of this Issue 2/2022

Endocrine 2/2022 Go to the issue

Original Article

Incidentally discovered papillary thyroid microcarcinoma in patients undergoing thyroid surgery for benign disease

Original Article

Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms

Original Article

Risk stratification in patients with anaplastic thyroid carcinoma: role of age

Brief report

Heterozygous POR gene mutations in a patient with congenital adrenal hyperplasia

Original Article

“Lymphocyte population in peripheral blood in children and adolescents with graves disease. Potential predictive tool for severity of the disease”

Original Article

Interaction effect of blood glucose and pressure on the risk of chronic kidney disease: a population-based prospective cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits